LA JOLLA, Calif., March 14 /PRNewswire/ -- ActivX Biosciences, Inc., a wholly-owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd., announced today that it has renewed its strategic collaborative agreement with Pfizer that encompasses discovery to developmental stage projects across multiple research sites of Pfizer's Global Research and Development organization. ActivX has previously announced an expansion of its collaboration with Pfizer in February 2005.
Under the terms of the agreement, ActivX will apply its novel chemical technologies and high-throughput protein analysis to a number of Pfizer programs spanning drug discovery, proteomic profiling, compound selectivity and biological activity, and mechanisms of toxicity.
"The Pfizer collaboration is an important component of our scientific and business strategy," stated Dr. John W. Kozarich, Chairman and President at ActivX. "Its renewal for a third year is a testimony to the value that the ActivX technology has added to Pfizer R&D programs," he added.
Financial terms of this transaction include an upfront technology access fee along with research support payments by Pfizer.
About ActivX Biosciences, Inc.
ActivX Biosciences, Inc. (www.activx.com), a wholly-owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd., in La Jolla, California, has drug discovery, proteomics technology and clinical development capabilities. The company applies proprietary chemical technologies and high-throughput protein analysis to the drug discovery and development process. By focusing on functional proteins, ActivX addresses disease mechanisms directly, in contrast to approaches such as expression profiling, in which the measured analyte is several steps removed from the site of drug action. ActivX and its partners are using its proprietary technology to address critical challenges in drug discovery, including selectivity profiling of candidate drug molecules across whole protein families in biological samples to guide their medicinal chemistry optimization; identifying novel drug targets and biomarkers; and characterizing off-target activities of candidate and established drugs to understand the basis for their efficacy and toxicity.
ActivX Biosciences, Inc.CONTACT: John W. Kozarich, Ph.D., Chairman and President of ActivXBiosciences, Inc., +1-858-526-2502
Web site: http://www.activx.com/
